Welcome to the world
of Théa Open Innovation
Théa Open Innovation aims to identify, assess and set up partnerships between start-ups universities and research teams’best innovative solutions to help develop new treatments for eyes diseases.
Latest news
European Investment Bank provides €150 million to Théa
The European Investment Bank provides €150 million in financing to
Iolyx Therapeutics Enters Strategic Agreement with Théa
Deal with Laboratoires Théa representing a total value of up
Sepul Bio, an innovative business unit of Théa, Doses First Participant in Phase 3 HYPERIONclinical trial of sepofarsen for CEP290-associated Leber Congenital Amaurosis Type 10
Clermont-Ferrand, France, Wednesday 1 October 2025 – Sepul Bio, an
The Théa Open Innovation Team
Mélissa CHERVY,
Scientific Assessement Officer
Marjorie BARDIN,
Executive Assistant
Jocelyn MARTIN,
Alliance Manager
Marie DAVAL,
Alliance Manager
Eric BARBAN,
Head of Business Assessment
Antoine JOYAUX,
Business Development Manager
Stéphane THUMELIN,
Head of Business Development
Gabriela SABORIO,
Early-stage Medical Director
Fabrice MERCIER,
Medical Technology Director
Laure PENIN-PEYTA,
Scientific Assessment Manager
Céline OLMIERE,
Head of Théa Open Innovation